Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Phase 1
Terminated
- Conditions
- Non-Hodgkin's Lymphoma
- Registration Number
- NCT00057447
- Lead Sponsor
- InterMune
- Brief Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)
International study with sites in the Czech Republic and Poland
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes) 6 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergy between IFN gamma-1b and Rituximab in follicular NHL?
How does IFN gamma-1b combination therapy compare to standard-of-care regimens in low-grade NHL patients?
Which biomarkers correlate with improved outcomes in NHL patients receiving IFN gamma-1b plus Rituximab?
What are the most common adverse events associated with IFN gamma-1b and Rituximab combination therapy?
Are there alternative immunomodulatory agents being studied in combination with Rituximab for NHL treatment?
Trial Locations
- Locations (1)
Intermune Inc
🇺🇸Brisbane, California, United States
Intermune Inc🇺🇸Brisbane, California, United States